NCT07132112RecruitingPhase 1
A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology1 site in 1 country30 target enrollmentStarted: October 28, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Incidence of treatment-emergent adverse events
Study Overview
Brief Summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •1. Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.
- •2. Aged 18 to 65 years (inclusive), regardless of gender.
- •Specific inclusion criteria:
- •3. Participants with systemic lupus erythematosus (SLE)
- •Meets the classification criteria for SLE in the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR);
- •Disease activity score SLEDAI-2000 ≥ 6, with at least one British Islet Lupus Assessment Group Index (BILAG-2004) Grade A (severe manifestations) or two Grade B (moderate manifestations) organ scores, or both; Or the disease activity score SLEDAI-2000 ≥ 8;
- •4. Participants with idiopathic inflammatory myopathy （IIM）
- •Complies with the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM)
- •Myositis antibody positive;
- •. Meets the definition of recurrence, refractory or progressive;
- •5. Participants with systemic sclerosis
- •. Meet the 2013 American College of Rheumatology (ACR) SSc criteria;
- •. SSc related antibodies are positive;
- •. Meets the definition of refractory or progressive recurrence
Exclusion Criteria
- •1. Within 3 weeks prior to lymphodepleting chemotherapy, complement inhibition therapy (such as Ecuzumab) has been used;
- •2. Received attenuated live vaccine within 4 weeks before lymphodepleting chemotherapy;
- •3. Having undergone major surgery within the 8 weeks prior to screening, or planning to undergo surgery during the study period;
- •4. Medical history of organ transplantation;
- •5. Previously received CAR-T product therapy targeting any target (excluding GT719 therapy);
- •6. According to the investigator's judgment, the situations that hinder participants from participating in the entire trial, confound the trial results, or participate in the trial that are not in the best interests of the participants.
Arms & Interventions
GT719 Injection treatment group
Experimental
GT719 Injection
Intervention: GT719 Injection (Biological)
Outcomes
Primary Outcomes
Incidence of treatment-emergent adverse events
Time Frame: 2 years
Safety assessments are conducted using the NCI-CTCAE version 5.0 standards
Proportion of participants experiencing dose limiting toxicity
Time Frame: 28 days
Proportion of participants experiencing dose limiting toxicity (DLT) within 28 days after cell infusion
Secondary Outcomes
- Efficacy outcomes for Inflammatory Myopathy(14 days; 1, 2, 3, and 6 months post GT719 infusion)
- Efficacy outcomes for SLE(14 days; 1, 2, 3 and 6 Months post GT719 infusion)
- Efficacy outcomes for Systemic Sclerosis(14 days; 1, 2, 3, and 6 months post GT719 infusion)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell MalignanciesHematological Malignancy (Leukemia- Lymphoma)NCT06948981Grit Biotechnology46
Recruiting
Phase 1
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune DiseasesNeurological Autoimmune DiseasesNCT07021209Grit Biotechnology30
Unknown
Phase 1
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid TumorsAdvanced Solid TumorsHRDBRCA MutationNCT03415659Hubei Biological Medicine Industrial Technology Institute Co., Ltd.85
Recruiting
Phase 1
Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic NeoplasmsCD70-positive Advanced Urologic NeoplasmsNCT05990621Changhai Hospital60
Not yet recruiting
Phase 1
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT06340490Guangdong Ruishun Biotech Co., Ltd24